W. Wu

Bortezomib therapy in myelofibrosis: a phase II clinical trial

S. Verstovsek, R. Mesa, A. Tefferi, 2008, Leukemia.

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

R. Mesa, C. Erlichman, S. Kaufmann, 2007, Leukemia.

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

R. Mesa, A. Tefferi, A. Pardanani, 2008, Leukemia.

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

A. Tefferi, Wenting Wu, A. Wolanskyj, 2007, Leukemia.

5-Azacitidine has limited therapeutic activity in myelofibrosis

S. Verstovsek, R. Mesa, A. Tefferi, 2009, Leukemia.

A Phase 1 Trial of Daily Oral Green Tea Extract in Asymptomatic, Rai Stage 0–II Patients with Chronic Lymphocytic Leukemia.

T. Shanafelt, C. Erlichman, S. Kaufmann, 2007 .